Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glucocorticoid + Sirolimus vs Glucocorticoid in newly diagnosed wAIHA
NCT07518277Not yet recruiting
- Sponsor
- Chenmiao
- Start
- Apr 2026
- Primary completion
- Apr 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of sirolimus in autoimmune hemolytic anemia (AIHA) (2 arms), sponsored by Chenmiao. Primary endpoint: 12-month sustained remission rate. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
sirolimus
03
Conditions
autoimmune hemolytic anemia (AIHA)
Beyond the preview
Go deeper on NCT07518277.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07518277.